Management of Abnormal DHEA-S Levels

Elevated DHEA-S Levels

• The approach to abnormal DHEA-S depends critically on whether levels are elevated or low, with elevated levels requiring systematic evaluation for androgen excess and potential neoplasms, while low levels primarily occur in primary adrenal insufficiency requiring replacement therapy 1
• Assess for signs of androgen excess including hirsutism, acne, male-pattern baldness, menstrual irregularities, and signs of virilization (clitoromegaly, voice deepening, increased muscle mass) 1
• Evaluate for features of other endocrine disorders such as truncal obesity, hypertension, and glucose intolerance 1
• Moderate elevations are most commonly associated with PCOS (affecting 4-6% of women) or non-classical congenital adrenal hyperplasia 1
• Obtain adrenal CT or MRI to exclude adrenal tumor 1
• Perform pelvic ultrasound in women to evaluate for ovarian pathology 1
• Clinical diagnosis based on menstrual irregularity, hirsutism, acne, and obesity is often sufficient for moderate elevations with PCOS features 1
• DHEA-S has moderate diagnostic accuracy for PCOS with pooled sensitivity and specificity around 70-75% 2
• Weight loss is first-line for overweight or obese patients with PCOS-related elevation 1
• Hormonal contraceptives regulate menstrual cycles and reduce androgen effects 1
• Metformin or other insulin-sensitizing agents if insulin resistance is present 1
• Anti-androgen therapy (spironolactone) for persistent hirsutism or acne 1
• Repeat DHEA-S measurements every 3-6 months until normalized or stable 1
• Monitor clinical symptoms of androgen excess and assess treatment response 1
• Long-term follow-up for persistent elevations to detect evolving pathology 1

Low DHEA-S Levels

• Low DHEA-S is a characteristic finding in primary adrenal insufficiency (PAI), along with low cortisol, elevated ACTH, and low aldosterone 3, 4
• Offer a 6-month trial of oral DHEA (10-50 mg, typically 25 mg daily) to women with PAI who have persistent symptoms despite optimized glucocorticoid and mineralocorticoid replacement 5, 4
• Dose guided by morning serum DHEA-S, androstenedione, and testosterone levels, which should be maintained in the normal range measured prior to DHEA ingestion 5, 4
• Continue therapy only if clinically effective after the 6-month trial 5, 4
• Use with caution as long-term effects are not fully established, with only limited objective evidence of clinical benefit from large studies 5, 4

Special Populations

• Regular monitoring without specific treatment is recommended for premature adrenarche, with follow-up every 6-12 months to monitor growth velocity, bone age, and pubertal development 6
• Evaluate further if signs of true central puberty develop 6
• DHEA-S monitoring is less critical than adjusting glucocorticoid and mineralocorticoid doses during pregnancy in PAI 5, 4

Evaluation and Management of Men with Low DHEA‑S and Pregnenolone

Laboratory Assessment for Primary Adrenal Insufficiency (PAI)

• Measure morning (8–10 AM) serum cortisol; a value < 138 nmol/L (5 µg/dL) is indicative of adrenal insufficiency. 7
• Obtain plasma ACTH concurrently; an ACTH level > 2 × the upper limit of normal confirms primary (rather than secondary) adrenal insufficiency. 7
• Assess aldosterone and plasma renin activity (PRA); low aldosterone together with elevated PRA reflects mineralocorticoid deficiency typical of PAI. 7
• Check serum electrolytes for hyponatremia and hyper‑kalemia, which support a diagnosis of mineralocorticoid deficiency. 7

Confirmatory Testing When Initial Hormones Are Inconclusive

• Perform a cosyntropin (ACTH) stimulation test if the morning cortisol is borderline (138–500 nmol/L) to definitively diagnose adrenal insufficiency. 7
• Evaluate morning total and free testosterone (by equilibrium dialysis) because men with PAI frequently have concurrent hypogonadism. [8][9]

Additional Hormonal Evaluation for Hypogonadism

• If testosterone is low, measure luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) to differentiate primary from secondary hypogonadism. [8][9]10
• Determine sex‑hormone‑binding globulin (SHBG) in men with obesity or borderline testosterone, as low SHBG can falsely lower total testosterone values. [8][9]10

Imaging Recommendations

• Order adrenal CT or MRI after PAI is confirmed to identify structural causes such as autoimmune adrenalitis, hemorrhage, infiltrative disease, or metastases. [11][12]
• Consider pituitary MRI when secondary adrenal insufficiency is suspected (low ACTH with low cortisol). 10

Clinical Management Priorities

• Initiate immediate glucocorticoid replacement (hydrocortisone 15–25 mg daily in divided doses) and mineralocorticoid replacement (fludrocortisone 0.05–0.2 mg daily) once PAI is diagnosed; delay increases morbidity and mortality. 7
• Routine DHEA supplementation is not required in men with PAI because testicular testosterone production provides sufficient androgenic activity. 7
• A trial of DHEA may be considered only in men with persistent symptoms despite optimized glucocorticoid/mineralocorticoid therapy, although evidence of benefit is limited. 7

Practical Considerations

• Collect cortisol and testosterone samples in the early morning (8–10 AM) to ensure accurate interpretation. [8][9]
• Review medication history for agents (e.g., glucocorticoids, opioids) that can suppress the hypothalamic‑pituitary‑adrenal axis. 7